Complement Inhibitor Fails in Trials for Geographic Atrophy

Complement inhibition as a means of halting the progression of geographic atrophy took a hit this week, with negative findings announced for two pivotal phase 3 clinical trials of lampalizumab.
Medscape Medical News

Full Story →